Cellectar Biosciences Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cellectar Biosciences Inc 's ROA in the first quarter of 2026?
Cellectar Biosciences Inc recorded a cumulative net loss of $-21 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -153.18%.

However, within the Healthcare sector 812 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4408, from total ROA ranking in the fourth quarter of 2025 at 5087.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-30.68 %	-41.2 %	-60.78 %	-53.39 %	-62.63 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-21	-22	-19	-29	-25
Return On Assets (TTM)	-153.18 %	-146.88 %	-107.97 %	-125.71 %	-90.74 %
CLRB's Total Ranking	# 4408	# 5087	# 4411	# 4536	# 4478
Total Assets (TTM) in million	11	15	15	14	16
Seq. Total Assets Change	-25.76 %	2.4 %	6.81 %	-14.63 %	-37.03 %
Seq. Net Income Change	-	-	-	-	-

CLRB's 5 Years Annual ROA >> Back to CLRB Management Effectiveness >> Compare CLRB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 385
Sector	# 813
Overall	# 4363

Return On Assets Statistics
High	Average	Low
-28.58 %	-112.53 %	-308.06 %
(Jun 30 2016)		(Dec 31 2023)

News about Cellectar Biosciences Inc Return on Assets ROA

Cellectar Biosciences Navigating Regulatory Milestones Amidst Market Turbulence

Cellectar Biosciences Inc. (NASDAQ: CLRB) finds itself at a critical juncture as various news reports illuminate a complex landscape of opportunities and challenges. Recent developments surrounding its lead therapy candidate, iopofosine I 131, highlight both the promise of regulatory advancements and the turbulence that accompanies market fluctuations.On July 23, 2024, Cellectar faced a rocky trajectory, beginning with news of positive treatment data for iopofosine in patients with Waldenstrom s Macroglobulinemia. The company announced an upcoming New Drug Application (NDA) submission expected in the fourth quarter, which could pave the way for significant progress in targeted treatments within this niche oncology space. This news initially inspired optimism among investors, potentially alluding to a bright future for the company and its promising therapy. However, the mood soured quickly as the share price dropped significantly up to 19.2% in one day after Cellectar updated investors on pivotal study results from its CLOVER WaM trial. While the data showed an impressive 80% overall response rate for iopofosine, the market was likely seeking more definitive guidance on long-term efficacy and safety, leading to investor jitters. Such a steep decline underlines the volatility that accompanies developments in clinical trials, where high expectations can lead to sharp reactions from the market.

Financial Statements
Cellectar Biosciences Inc 's Assets	$ 11 million	CLRB's Balance sheet
Cellectar Biosciences Inc 's Income	$ -6 million	Quarterly CLRB's Income Statement
CLRB's Income by Division		See CLRB's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-41.2 %	110.54 %	-44.15 %	-41.76 %	-36.58 %
Total Assets in million	15	25	12	22	37
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-22	-45	-43	-29	-24
Annual Return On Assets	-145.48 %	-175.01 %	-353.5 %	-132.02 %	-64.84 %

CLRB's 5 Years Annual ROA >> Back to CLRB Management Effectiveness >> Compare CLRB ROA to its Competitors

More Return On Assets Ratios
CLRB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CLRB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CLRB's Competitors
Subscribers only: Roa for Cellectar Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for CLRB's Customers

You may also want to know
CLRB's Roi	CLRB's Inventory Turnover Ratio	CLRB's Growth Rates	CLRB's Dividend Comparisons
	CLRB's Profitability Ratios	CLRB's Asset Turnover Ratio	CLRB's Dividend Growth
CLRB's Roe	CLRB's Valuation Ratios	CLRB's Financial Strength Ratios	CLRB's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.